Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer)
2013-000277-72Phase 3Completed
- Sponsor
- Array BioPharma
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of binimetinib in low-grade serous ovarian carcinoma (LGSOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Array BioPharma. Primary endpoint: Progression-free survival (BICR). Started Jul 2013; status: completed.
02
Drugs
binimetinib
03
Conditions
low-grade serous ovarian carcinoma (LGSOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2013-000277-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000277-72.